Abstract:Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the protein, while also generating memory cells to respond quickly in the event of future pathogen encounters. Available mRNA vaccines, such as Pfizer-BioNTech and Moderna, were developed and authorized for emergency use within a year. These vaccines require extensive cold chain storage, antigen delivery, potential immune response variability optimization, and sophisticated manufacturing process. To improve their effectiveness, stability, and delivery, efforts are underway to explore next-generation mRNA vaccines. Research is focused on enhancing the stability of mRNA vaccines, particularly their temperature sensitivity, to facilitate easier storage and distribution. Self-amplifying mRNA vaccines are also being developed to generate multiple copies of mRNA within cells, potentially leading to a higher production of protein and a stronger immune response. Studies are also exploring new delivery systems using specialized nanoparticles and liposomes to specifically target certain immune cells. Additionally, the development of combination vaccines, including multiple mRNA sequences in single vaccine, is being investigated to protect against multiple strains or variants of particular pathogen simultaneously. Direct delivery of mRNA vaccines into the skin is being explored as a means of enhancing immune response and reducing the required vaccine dose. In summary, messenger RNA vaccines represent a promising new approach to vaccination, with ongoing research aimed at improving their effectiveness, stability, and delivery

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines

A Novel Self‐Amplifying mRNA with Decreased Cytotoxicity and Enhanced Protein Expression by Macrodomain Mutations

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines

Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines

In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins

Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations

Amplification of Protein Expression by Self-Amplifying mRNA Delivered in Lipid Nanoparticles Containing a β-Aminoester Ionizable Lipid Correlates with Reduced Innate Immune Activation

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Introduction to RNA Vaccines Post COVID-19

A new generation of vaccines based on alphavirus self-amplifying RNA

Vaccines' New Era-RNA Vaccine

Advances in the design and delivery of RNA vaccines for infectious diseases

Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity

Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome

Cancer vaccine strategies using self-replicating RNA viral platforms

Recent Advances in mRNA Vaccine Development

Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines